Edward Holland, MD, chief medical advisor, discussed an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.
This content originally appeared on our sister site, Ophthalmology Times.
OncLive spoke with Edward Holland, MD, chief medical advisor, Aurion Biotech, about the company's investigation of injectable endothelial cells, where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease as well as other forms of corneal edema.
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.